Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. - Wikidata - wikimedia - TriplyDB

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

http://www.wikidata.org/entity/Q45059332

about

Management of antipsychotic-related weight gain Genetics of antipsychotic treatment emergent weight gain in schizophrenia.The impact of hyperactivity and leptin on recovery from anorexia nervosa.A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review.Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary Evidence Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.Atypical antipsychotic-induced weight gain: insights into mechanisms of action.Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients.Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.Plasma leptin and antipsychotic-induced body weight gain.Sex Differences in Leptin Control of Cardiovascular Function in Health and Metabolic Diseases.Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics

P2860

Q24610124-DBD450D8-9678-4D45-B1E7-615DAD0953F9 Q33257886-79D426B8-9B1D-46EC-ADEC-54DD1C4570C4 Q33560869-A43939FA-9AAF-4D1A-9267-02F1546FC29B Q33888821-BA0F3AB0-1F47-4710-8EA0-8CF90B915337 Q33942644-E95B04CB-EAF9-401F-8BEB-C7CAC1F79E40 Q34056408-9F5054AF-AAB7-4015-A0EA-72703F7C8229 Q34197980-4256AE53-FBC6-4AA3-9A09-61D8725AFB8A Q35156543-BB5ACA82-B63F-446F-A8DE-E8FC123BF30C Q35566086-91AFAEEA-5E48-4448-82F2-D41B74FFEA23 Q37047473-B35E8873-1BFB-4A01-8242-D9D1599F4B45 Q37060706-C45545EA-C2B6-4F1E-AE4D-C36FB7372C34 Q37160453-476E81F9-D1FA-4CCA-853B-7031F1431331 Q37178192-A1EF27A7-A574-4D26-91F5-CE02AB7978C1 Q37387054-68DE8DA7-06E6-422A-BF9D-0AA73EF7C459 Q37963571-1E5A10D1-37D7-4499-AB50-9E56D0DE4BFE Q41733975-C072B7D3-826D-4AB7-A790-71711E776F19 Q46444830-1F04ABC0-A912-4A59-8619-D65A1BCEF34E Q47302385-98C561BA-A612-469F-8499-0998C708FBA7 Q47303990-D45400DF-BBF2-4BAF-853B-D31847512FA6 Q47371630-9614B9A5-808B-4BD8-992D-1617DC66A293 Q49971662-39624C7A-EA9D-492E-9FD3-D404053B28D2 Q54662194-5DA081A8-29EF-4B24-BD5D-9575E6132A7C Q59206898-1B07AEC5-0ECC-4AED-A856-9E992A540D7A

P2860

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

http://www.wikidata.org/entity/Q45059332

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@en

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@nl

type

label

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@en

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@nl

prefLabel

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@en

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@nl

P1433

Q45059332-0FE6E26D-7A7E-4162-BF3A-3907EBCD41A2

P1476

Q45059332-F9418B86-02FD-41F9-A588-8A8C5F1B2A65

P2093

Q45059332-2A59F0B1-F8CD-4D3E-9450-DF9F75A86CCF

Q45059332-4420BC1B-BD6C-4518-AC94-E893BB16FF9B

Q45059332-5DE73919-64FF-43DC-9249-FDBAD62BEAB2

Q45059332-6BE6CBE3-F268-4384-BEC0-3D25D0DD50DB

Q45059332-87E1C7D5-EA28-4D0A-B44F-BD517A3C91D0

Q45059332-898164A6-9A8F-45DA-85B5-C557D4CAC9BE

P2860

Q45059332-12776E0F-78CA-4E0C-BE47-2588AF40C265

Q45059332-2139CA26-3070-44A3-B154-C254C577A230

Q45059332-31B0B968-9D40-49F1-B0C8-02432ADC479C

Q45059332-4B718B92-89A2-4404-BD91-8ED36E2A8A58

Q45059332-5140B6D0-6C0A-43B1-911F-2DABA9392162

Q45059332-579F1124-96B2-4B2F-9F6F-5293709B4961

Q45059332-5F582A71-7EE7-451F-93A7-F33D72E7E742

Q45059332-680ACEC1-9812-4A16-804C-4291374BAB72

Q45059332-6EB0B2D2-04CF-4DC1-89B7-2B101D4B6290

Q45059332-6F9B7DE7-CDE8-48CA-B5DA-99803ECEE942

P2888

Q45059332-5C0C67E7-D089-4D58-A23A-4618DCC7A1EF

P304

Q45059332-3D66A918-3E66-4065-9FB0-51F2B96D1531

P31

Q45059332-33E73647-4AD2-4860-B440-9426AB2FBE64

P356

Q45059332-22B11499-D992-4E1C-B869-8D2AC4C0E164

P407

Q45059332-18F43171-8E1B-4B9A-83CD-9471E3318EE8

P433

Q45059332-807B83A2-F104-4491-9261-3DC1F8B9819B

P478

Q45059332-A927D8A3-43E9-48CB-A523-8949637F5748

P577

Q45059332-1F4E79CF-360F-461B-9C5C-5F99D19535C2

P5875

Q45059332-6270DF85-989E-4FE0-AD83-0517816F61D1

P6179

Q45059332-A088482C-8726-4D65-9926-E14FA3C42BD1

P698

Q45059332-B80C5FC3-9A4A-4F8E-816E-370C2929B2C4

P921

Q45059332-62E2BFC7-7437-453B-A0C1-FEB68BEFBEFE

P356

P1433

Neuropsychopharmacology

P1476

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.

@en

P2093

Angela K Melson

http://www.w3.org/2001/XMLSchema#string

Angela Luber

http://www.w3.org/2001/XMLSchema#string

Dan W Haupt

http://www.w3.org/2001/XMLSchema#string

John W Newcomer

http://www.w3.org/2001/XMLSchema#string

Julie A Schweiger

http://www.w3.org/2001/XMLSchema#string

Justin Maeda

http://www.w3.org/2001/XMLSchema#string

P2860

Positional cloning of the mouse obese gene and its human homologue

Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

Congenital leptin deficiency is associated with severe early-onset obesity in humans

Adipose tissue as an endocrine organ

Leptin sensitive neurons in the hypothalamus.

The perils of portliness: causes and consequences of visceral adiposity.

Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Increased obese mRNA expression in omental fat cells from massively obese humans.

P2888

P304

184-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300563

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8346656

http://www.w3.org/2001/XMLSchema#string

P6179

1033460609

http://www.w3.org/2001/XMLSchema#string

P698

15367925

http://www.w3.org/2001/XMLSchema#string

P921